Epileptic seizures nearly vanish after experimental gene therapy in early trial
Epileptic seizures nearly vanish after experimental gene therapy in early trial
Epileptic seizures nearly vanish after experimental gene therapy in early trial
Key points
اہم نکات
मुख्य बातें
- Three people with epilepsy that resisted drug treatment saw their seizures fall by more than 90 percent after an experimental gene therapy was infused directly into their brains, Nature reports.
- The early-stage trial targeted a small patch of brain tissue causing the seizures, using a virus to deliver a gene that makes neurons sensitive to a drug, clozapine, which works like a dimmer switch for the treatment.
- Around two months later, monthly seizures had dropped from 4.5 to 0.5 for two participants and from 4 to zero for the third, with no serious side effects.
- Three people with epilepsy that resisted drug treatment saw their seizures fall by more than 90 percent after an experimental gene therapy was infused directly into their brains, Nature reports.
- The early-stage trial targeted a small patch of brain tissue causing the seizures, using a virus to deliver a gene that makes neurons sensitive to a drug, clozapine, which works like a dimmer switch for the treatment.
- Around two months later, monthly seizures had dropped from 4.5 to 0.5 for two participants and from 4 to zero for the third, with no serious side effects.
- Three people with epilepsy that resisted drug treatment saw their seizures fall by more than 90 percent after an experimental gene therapy was infused directly into their brains, Nature reports.
- The early-stage trial targeted a small patch of brain tissue causing the seizures, using a virus to deliver a gene that makes neurons sensitive to a drug, clozapine, which works like a dimmer switch for the treatment.
- Around two months later, monthly seizures had dropped from 4.5 to 0.5 for two participants and from 4 to zero for the third, with no serious side effects.
Three people with epilepsy that resisted drug treatment saw their seizures fall by more than 90 percent after an experimental gene therapy was infused directly into their brains, Nature reports. The early-stage trial targeted a small patch of brain tissue causing the seizures, using a virus to deliver a gene that makes neurons sensitive to a drug, clozapine, which works like a dimmer switch for the treatment. Around two months later, monthly seizures had dropped from 4.5 to 0.5 for two participants and from 4 to zero for the third, with no serious side effects. The results, reported in the New England Journal of Medicine by neurosurgeon Yang Dai of Xuanwu Hospital in Beijing, come with a caution: the trial was very small, with no control group, and the long-term effects of the drug are still unclear.
Three people with epilepsy that resisted drug treatment saw their seizures fall by more than 90 percent after an experimental gene therapy was infused directly into their brains, Nature reports. The early-stage trial targeted a small patch of brain tissue causing the seizures, using a virus to deliver a gene that makes neurons sensitive to a drug, clozapine, which works like a dimmer switch for the treatment. Around two months later, monthly seizures had dropped from 4.5 to 0.5 for two participants and from 4 to zero for the third, with no serious side effects. The results, reported in the New England Journal of Medicine by neurosurgeon Yang Dai of Xuanwu Hospital in Beijing, come with a caution: the trial was very small, with no control group, and the long-term effects of the drug are still unclear.
Three people with epilepsy that resisted drug treatment saw their seizures fall by more than 90 percent after an experimental gene therapy was infused directly into their brains, Nature reports. The early-stage trial targeted a small patch of brain tissue causing the seizures, using a virus to deliver a gene that makes neurons sensitive to a drug, clozapine, which works like a dimmer switch for the treatment. Around two months later, monthly seizures had dropped from 4.5 to 0.5 for two participants and from 4 to zero for the third, with no serious side effects. The results, reported in the New England Journal of Medicine by neurosurgeon Yang Dai of Xuanwu Hospital in Beijing, come with a caution: the trial was very small, with no control group, and the long-term effects of the drug are still unclear.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।